Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 98 of the 103 references it cites were found in a registry or an index, and 1 are not checked yet; 61 of the 148 sources its claims cite were checked for support.

The risks versus the benefits of pharmacological intervention in social anxiety disorder in children

Open access
Hofmann, Stefan G., Kasch, Chantal, Pereira, Bruno, Barbosa, Carolina, Andreoli, Giovanbattista · 2025 · Expert Review of Neurotherapeutics

Abstract

Introduction Many children are affected by social anxiety disorder (SAD). Pharmacotherapy, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), may be indicated, but a clear understanding of the risks and benefits associated with these pharmacological treatments is needed. Areas covered This expert review explores the risks and benefits of pharmacotherapy for treating SAD in children. Expert opinion Pharmacotherapy may be considered as a treatment when symptoms are complex or severe or when effective psychotherapy, such as cognitive behavioral therapy (CBT), is not accessible. We recommend that clinicians collaborate closely with parents, pediatricians, and psychiatrists in the treatment planning process, while monitoring the effects of pharmacotherapy. Future research should prioritize the personalization of treatments.

Verified 2026-10-05 · 1 reference not checked yet

Overview

CoChat Summary

TL;DR

This expert review concludes that CBT should remain first-line for pediatric social anxiety disorder (SAD), with SSRIs/SNRIs considered mainly when symptoms are severe or psychotherapy is inaccessible or ineffective. Pharmacotherapy can reduce anxiety symptoms, but it carries risks including suicidality, behavioral changes, and physical side effects, and no SSRI or SNRI is FDA-approved for SAD in children.

Key findings

  • The 6-month prevalence of SAD in children is estimated at 5%; comorbidities are common, with rates of 77% in ages 6–9, 74% in ages 10–14, and 69% in ages 15–18 in one cited study.
  • Medication trials show benefit over placebo: sertraline response 54.9% vs 23.7% for placebo after 12 weeks; fluvoxamine “much improved” in 76% vs 29% for placebo; venlafaxine response 56% (95% CI 47–64) vs 37% (95% CI 29–45) for placebo, with three venlafaxine-treated participants developing treatment-emergent suicidality.
  • CBT is supported as first-line treatment; CBT combined with sertraline is more effective than either alone, and CBT is associated with lower dropout than pharmacological treatments.
  • Risks include increased suicidality, adverse behavioral changes (e.g., hyperactivity, irritability, impulsivity, hostility), physical side effects (e.g., gastrointestinal discomfort, sleep disturbance, reduced height growth/weight gain with fluoxetine), and an FDA black box warning for SSRIs; no SSRI or SNRI is officially FDA-approved for SAD.

Methods

  • Expert review/scoping review of RCTs using PubMed and Scopus up to August 2024, with search terms “Pharmacotherapy treatment,” “social anxiety disorder,” and “children.”
  • The search yielded 762 records; after duplicate removal, two authors independently and blindly reviewed 680 abstracts, leading to inclusion of 8 RCTs.
  • Inclusion criteria: RCTs; experimental group received pharmacotherapy alone or combined with psychotherapy; child/adolescent sample; diagnosis of SAD or anxiety disorders including SAD. The review also included 2 reviews and 4 meta-analyses, plus one additional meta-analysis found through references.

Limitations

  • The paper states that literature on long-term effects of SSRIs/SNRs in children is scarce, findings on prenatal SSRI exposure are conflicting, and biological benefits research is limited.
  • It notes that one included meta-analysis had moderate heterogeneity and moderate risk of bias, and that one RCT had a small sample size (N = 30), limiting generalizability.
  • Evident from the text: this is an expert/scoping review rather than a systematic meta-analysis, with no quantitative pooling or formal risk-of-bias assessment reported; the FDA warning cited was based primarily on adolescents with major depressive disorder, not SAD.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1080/14737175.2025.2461763

Cites

98 of 103 references verified0 citation errors · 4 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

39 Valid · 15 Not valid · 63 Not checked · 35 Own results and interpretations

72 more claims · 25 with their cited sources checked

Create a free account to see all 152 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 49
  • Probably not a substantial claim. 33
  • Borderline: one of the tests for a substantial claim is unclear. 1
  • The quote only partly states this claim. 4

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 97 references

Research works printed but not linked: 2

  1. 10.1056/nejm200104263441703 · DOI · Paper page
  2. 10.31887/DCNS.2011.13.4/ikodish · DOI · Paper page

Cited by

See all 2

Metadata

Authors
Hofmann, S. G., Kasch, C., Pereira, B., Barbosa, C., & Andreoli, G.
Affiliations
Philipps University of Marburg (DE)
Corresponding author
Hofmann, Stefan G.
Venue
Expert Review of Neurotherapeutics
Published
2025-02-12
Volume
25
Issue
3
Pages
299-310
ISSN
  • 1473-7175 (ISSN-L)
  • 1744-8360
OpenAlex
W4407555893
Cited by
2
References
97
Citations by year
2026: 1 · 2025: 1
FWCI
0.33
Type
journal article
Language
en
Open access
Locations
  • Expert Review of Neurotherapeutics (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
Keywords
social anxiety disorder, children, pharmacotherapy, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, treatment risks and benefits, cognitive behavioral therapy, treatment planning, parental collaboration, treatment monitoring, personalized treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The risks versus the benefits of pharmacological intervention in social anxiety disorder in children. https://app.cochat.ai/papers/10.1080/14737175.2025.2461763
The paper
Hofmann, S. G., Kasch, C., Pereira, B., Barbosa, C., & Andreoli, G. (2025). The risks versus the benefits of pharmacological intervention in social anxiety disorder in children. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2025.2461763

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.